A few days before the arrival of Alli pill to treat obesity sold without a prescription, the French Agency for Safety of Health Products has reiterated its warning on medicines for weight loss.
As a reminder, Alli, launched in the U.S. in June 2007, is in the intestines by eliminating a quarter of the fat ingested. Taking this treatment (2 € per day for 6 months) is accompanied by a reduced-calorie diet, low in fat and physical exercise to help weight loss.
Specialists Philippe Lechat, Director of the Evaluation of Medicinal and Biological Products and Anne Castot, Head of Evaluation, recalled that overweight must be accompanied by a medical care, over the long haul, to achieve sustainable results.
Moreover, this support is most essential since it plays a vital role for sustainable change dietary habits and the maintenance of weight loss upon discontinuation of treatment.
The experts also revealed the adverse effects of the diet pill Alli, soon for sale without a prescription in France. This medicine can cause gastrointestinal side effects, including flatulence and stool incontinence, it is not associated with a low fat diet.
To monitor the occurrence of adverse effects of this product, a regional pharmacovigilance center will be named.
No comments:
Post a Comment